Table 4.
Serous |
Mucinous |
|||||
---|---|---|---|---|---|---|
Benign |
Borderline |
Malignant |
Benign |
Borderline |
Malignant |
|
(n = 13) | (n = 9) | (n = 24) | (n = 12) | (n = 7) | (n = 3) | |
p53* |
0a |
0 (0–1)b |
4 (0–4)b |
0 |
0 |
1 (0–4)c |
p21* |
3 (0–4)d,e |
4 (1–4)f |
4 (1–4)f |
0.5 (0–4) |
2 (1–4) |
2 (2–4) |
bax** |
0 (0–2) |
1 (0–4) |
1 (0–6) |
0 (0–1)g |
0 (0–4) |
1 (0–3) |
bcl-2** |
0 (0–2) |
0 (0–4) |
0 (0–4) |
0 |
0 |
0 |
c-kit** |
1 (0–6) |
0 (0–4) |
0.5 (0–12) |
0 (0–4) |
0 (0–1) |
0 |
Telomerase* |
0 (0–3) |
0 (0–2) |
0 (0–2) |
0 |
0 (0–3) |
1 (0–3) |
Metallothionein** | 2 (0–6) | 4 (1–6)i | 6 (0–12)i | 0 (0–9) | 2 (0–12)j | 2 (1–6) |
Data were presented as median (min-max). * Nuclear staining score. ** Quick score.
a,e,gP < 0.05 vs. borderline and malignant serous.
b,fP < 0.05 vs. benign and borderline mucinous.
c,iP < 0.05 vs. benign serous and benign mucinous.
d,jP < 0.05 vs. benign mucinous.